LinkedIn post on Regeneron’s Praluent pricing and market rollout

LinkedIn post on Regeneron’s Praluent pricing and market rollout The passage discusses drug pricing, market expectations, and physician usage surveys for Praluent. It contains no concrete allegations, financial flows, or links to high‑profile political or intelligence actors. The information is largely public and offers no actionable investigative leads. Key insights: Regeneron CEO Leonard Schleifer comments on pricing and access.; Praluent price is 46% higher than analyst forecasts.; Physician survey suggests broader off‑label use than label.